Copyright
©The Author(s) 2025.
World J Gastroenterol. Jul 21, 2025; 31(27): 109459
Published online Jul 21, 2025. doi: 10.3748/wjg.v31.i27.109459
Published online Jul 21, 2025. doi: 10.3748/wjg.v31.i27.109459
Table 1 Clinical characteristics of patients with Crohn's disease in training and validation cohorts
| Clinical characteristics | Training cohort (n = 156) | Validation cohort (n = 64) | P value |
| Age (years) | 25.00 (20.00, 31.00) | 24.00 (19.50, 29.00) | 0.351 |
| Gender (male/female) | 111/45 | 53/11 | 0.071 |
| Disease duration (months) | 14.50 (7.00, 36.00) | 12.00 (5.00, 46.00) | 0.706 |
| Montreal location, n (%) | |||
| Ileal (L1) | 21 (13.5) | 15 (23.5) | 0.346 |
| Colonic (L2) | 43 (27.6) | 18 (28.1) | 0.268 |
| Ileocolonic (L3) | 92 (58.9) | 31 (48.4) | 0.725 |
| Montreal behavior, n (%) | |||
| Nonstricturing, nonpenetrating (B1) | 105 (67.3) | 46 (71.9) | 0.356 |
| Stricturing (B2) | 39 (25.0) | 14 (21.9) | 0.623 |
| Penetrating (B3) | 22 (14.1) | 11 (17.2) | 0.561 |
| Perianal disease modifier (P) | 82 (52.6) | 33 (51.6) | 0.893 |
| Smoking (yes) | 8 (5.1) | 4 (6.3) | 0.739 |
| CRP (mg/L) | 12.95 (4.05, 30.16) | 14.60 (2.17, 27.06) | 0.438 |
| ESR (mm/h) | 26.50 (13.00, 36.00) | 22.00 (12.00, 31.00) | 0.252 |
| ALB (g/L) | 37.00 (33.90, 40.30) | 39.40 (34.70, 42.80) | 0.104 |
| WBC (× 109/L) | 6.49 ± 2.19 | 7.93 ± 1.56 | 0.105 |
| HBI | 6.00 (5.00, 8.00) | 6.50 (5.00, 7.00) | 0.388 |
| Previous abdominal surgery (yes), n (%) | 18 (11.5) | 9 (14.1) | 0.604 |
| Previous steroids or immunomodulators use (yes), n (%) | 69 (44.2) | 26 (40.6) | 0.624 |
- Citation: Li S, Zhu C, Tong L, Zheng XM, Rong C, Gao YK, Yuan DC, Wu XW. Correlation between radiomic features of Crohn's disease and secondary loss of response to infliximab. World J Gastroenterol 2025; 31(27): 109459
- URL: https://www.wjgnet.com/1007-9327/full/v31/i27/109459.htm
- DOI: https://dx.doi.org/10.3748/wjg.v31.i27.109459